Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Jan 3;3(1):e1919896.
doi: 10.1001/jamanetworkopen.2019.19896.

Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses

Isabelle Thomassin-Naggara  1   2   3 , Edouard Poncelet  4 , Aurelie Jalaguier-Coudray  5 , Adalgisa Guerra  6 , Laure S Fournier  7 , Sanja Stojanovic  8 , Ingrid Millet  9 , Nishat Bharwani  10 , Valerie Juhan  11 , Teresa M Cunha  12 , Gabriele Masselli  13 , Corinne Balleyguier  14 , Caroline Malhaire  15 , Nicolas F Perrot  16 , Elizabeth A Sadowski  3   17 , Marc Bazot  1   2 , Patrice Taourel  9 , Raphaël Porcher  18 , Emile Darai  19   20 , Caroline Reinhold  3   21 , Andrea G Rockall  3   10   22
Affiliations
Comparative Study

Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses

Isabelle Thomassin-Naggara et al. JAMA Netw Open. .

Abstract

Importance: Approximately one-quarter of adnexal masses detected at ultrasonography are indeterminate for benignity or malignancy, posing a substantial clinical dilemma.

Objective: To validate the accuracy of a 5-point Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) score for risk stratification of adnexal masses.

Design, setting, and participants: This multicenter cohort study was conducted between March 1, 2013, and March 31, 2016. Among patients undergoing expectant management, 2-year follow-up data were completed by March 31, 2018. A routine pelvic MRI was performed among consecutive patients referred to characterize a sonographically indeterminate adnexal mass according to routine diagnostic practice at 15 referral centers. The MRI score was prospectively applied by 2 onsite readers and by 1 reader masked to clinical and ultrasonographic data. Data analysis was conducted between April and November 2018.

Main outcomes and measures: The primary end point was the joint analysis of true-negative and false-negative rates according to the MRI score compared with the reference standard (ie, histology or 2-year follow-up).

Results: A total of 1340 women (mean [range] age, 49 [18-96] years) were enrolled. Of 1194 evaluable women, 1130 (94.6%) had a pelvic mass on MRI with a reference standard (surgery, 768 [67.9%]; 2-year follow-up, 362 [32.1%]). A total of 203 patients (18.0%) had at least 1 malignant adnexal or nonadnexal pelvic mass. No invasive cancer was assigned a score of 2. Positive likelihood ratios were 0.01 for score 2, 0.27 for score 3, 4.42 for score 4, and 38.81 for score 5. Area under the receiver operating characteristic curve was 0.961 (95% CI, 0.948-0.971) among experienced readers, with a sensitivity of 0.93 (95% CI, 0.89-0.96; 189 of 203 patients) and a specificity of 0.91 (95% CI, 0.89-0.93; 848 of 927 patients). There was good interrater agreement among both experienced and junior readers (κ = 0.784; 95% CI, 0.743-0824). Of 580 of 1130 women (51.3%) with a mass on MRI and no specific gynecological symptoms, 362 (62.4%) underwent surgery. Of them, 244 (67.4%) had benign lesions and a score of 3 or less. The MRI score correctly reclassified the mass origin as nonadnexal with a sensitivity of 0.99 (95% CI, 0.98-0.99; 1360 of 1372 patients) and a specificity of 0.78 (95% CI, 0.71-0.85; 102 of 130 patients).

Conclusions and relevance: In this study, the O-RADS MRI score was accurate when stratifying the risk of malignancy in adnexal masses.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Thomassin-Naggara reported receiving personal fees and nonfinancial support from General Electric and personal fees from Siemens, Hologic, Canon, and Guerbet outside the submitted work. Dr Fournier reported receiving grants from Invectys and speaking fees from General Electric, Novartis, Sanofi, and Janssen Pharmaceuticals outside the submitted work. Dr Balleyguier reported receiving personal fees and nonfinancial support from General Electric and personal fees from Siemens, Samsung Group, and the Bracco Group outside the submitted work. Dr Rockall reported receiving an educational speaker fee from Guerbet. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Population Flow Diagram
MR indicates magnetic resonance; MRI, magnetic resonance imaging.
See this image and copyright information in PMC

Comment in

References

    1. Curtin JP. Management of the adnexal mass. Gynecol Oncol. 1994;55(3, pt 2):-. doi:10.1006/gyno.1994.1340 - DOI - PubMed
    1. Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers: a Cochrane systematic review. Gynecol Oncol. 2012;126(2):286-290. doi:10.1016/j.ygyno.2012.04.012 - DOI - PubMed
    1. Meys EMJ, Kaijser J, Kruitwagen RFPM, et al. . Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2016;58:17-29. doi:10.1016/j.ejca.2016.01.007 - DOI - PubMed
    1. Froyman W, Landolfo C, De Cock B, et al. . Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019;20(3):448-458. doi:10.1016/S1470-2045(18)30837-4 - DOI - PubMed
    1. Alcázar JL, Pascual MA, Graupera B, et al. . External validation of IOTA simple descriptors and simple rules for classifying adnexal masses. Ultrasound Obstet Gynecol. 2016;48(3):397-402. doi:10.1002/uog.15854 - DOI - PubMed

Publication types